Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF)

International Journal of Cardiology

Volumn 200, Issue , 2015, Pages 15-19

  Capuano, Annalisa ^a   Scavone, Cristina ^a   Vitale, Cristiana ^b,c   Sportiello, Liberata ^a   Rossi, Francesco ^a   Rosano, Giuseppe M C ^b,c   Coats, Andrew J Stewart ^d,e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Aldosterone; Eplerenone; Heart failure; HFpEF; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; EPLERENONE; GALECTIN; GALECTIN 3; GELATINASE B; PLACEBO; PROCOLLAGEN; PROCOLLAGEN C PROTEINASE; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COMORBIDITY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; EXERCISE TEST; GYNECOMASTIA; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART REINFARCTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPONATREMIA; MASTALGIA; METABOLIC ACIDOSIS; NATRIURESIS; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VAGINA BLEEDING; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PHYSIOLOGY;

HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPIRONOLACTONE; STROKE VOLUME;

EID: 84941952548     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.07.038     Document Type: Review

References (21)

1. C.W. Yancy, M. Jessup, B. Bozkurt, and et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol. 62 2013 147 239
2. B. Taslima, and S.M. Mathew Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma Curr. Cardiovasc. Risk Rep. 5 2011 440 449
3. M. Komajda Current challenges in the management of heart failure Circ. J. 79 2015 948 953
4. B. Pitt, F. Zannad, W.J. Remme, and et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure N. Engl. J. Med. 341 1999 709 717
5. B. Pitt, W. Remme, F. Zannad, and et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321
6. F. Zannad, J.J. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N. Engl. J. Med. 364 2011 11 21
7. A. Deswal, P. Richardson, B. Bozkurt, and D.L. Mann Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF) J. Card. Fail. 17 2011 634 642
8. K. Kampourides, D. Tziakas, G. Chalikias, and et al. Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone Am. J. Cardiol. 110 2012 1085 1091
9. F. Edelmann, R. Wachter, A.G. Schmidt, and et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial JAMA 309 2013 781 791
10. B. Pitt, M.A. Pfeffer, S.F. Assmann, and et al. Spironolactone for heart failure with preserved ejection fraction N. Engl. J. Med. 370 2014 1383 1392
11. K.M. Kurrelmeyer, Y. Ashton, J. Xu, S.F. Nagueh, G. Torre-Amione, and A. Deswal Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction J. Card. Fail. 20 2014 560 568
12. K. Patel, G.C. Fonarow, D.W. Kitzman, and et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction JACC Heart Fail. 1 2013 40 47
13. F. Edelmann, V. Holzendorf, R. Wachter, and et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial Eur. J. Heart Fail. 17 2015 214 223
14. A. Gupta, C.G. Schiros, K.K. Gaddam, and et al. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy J. Hum. Hypertens. 29 2015 241 246
15. L.H. Lund, E. Donal, E. Oger, and et al. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction Eur. J. Heart Fail. 16 2014 992 1001
16. A.J. Reyes, W.P. Leary, G. Crippa, M.F. Maranhão, and R. Hernández-Hernández The aldosterone antagonist and facultative diuretic eplerenone: a critical review Eur. J. Intern. Med. 16 2005 3 11
17. C. Bavishi, S. Ather, A. Bambhroliya, and et al. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions Am. J. Cardiol. 113 2014 1834 1838
18. H.K. Parthasarathy, J. Ménard, W.B. White, and et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism J. Hypertens. 29 2011 980 990
19. J.E. Basaraba, and A.R. Barry Pharmacotherapy of heart failure with preserved ejection fraction Pharmacotherapy 35 2015 351 360
20. A.J. Stewart Coats, and L.G. Shewan The management of heart failure with preserved ejection fraction (HFpEF) Int. Cardiovasc. Forum J. 1 2014 108 112
21. M. Senni, A. Gavazzi, F. Oliva, IN HF Outcome Investigators, and et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry Int. J. Cardiol. 173 2014 163 169